Page last updated: 2024-08-05 13:33:32
aminopiperidine
null
ChEBI ID: 48588
Members (3)
Member | Definition | Role |
---|---|---|
AZD3463 | A member of the class of indoles that is 1H-indole substituted by a 2-[4-(4-aminopiperidin-1-yl)-2-methoxyanilino]-5-chloropyrimidin-4-yl group at position 3. It is an orally bioavailable dual inhibitor of ALK and IGF1R with Ki value of 0.75 nM for ALK. | AZD3463 |
crenolanib | A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a 8-(4-aminopiperidin-1-yl)quinolin-2-yl group at position 1 and by a (3-methyloxetan-3-yl)methoxy group at position 5. It is an inhibitor of type III tyrosine kinases, PDGFRalpha/beta and FLT3 (IC50 of 11, 3.2, and 4 nM). Currently under clinical development for the treatment of acute myeloid leukemia. | crenolanib |
linagliptin | A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes. | linagliptin |
Research
Studies (643)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 14 (2.18) | 29.6817 |
2010's | 440 (68.43) | 24.3611 |
2020's | 189 (29.39) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 153 (22.70%) | 5.53% |
Reviews | 103 (15.28%) | 6.00% |
Case Studies | 25 (3.71%) | 4.05% |
Observational | 13 (1.93%) | 0.25% |
Other | 380 (56.38%) | 84.16% |